Text Size

Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

This study has been terminated.
(Recruitment difficult and enrolment low: decision was made to stop the study.)
Sponsor:
Collaborator:
Louise & Alan Edwards Foundation - McGill Centre for Research on Pain
Information provided by:
McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00689585
First received: May 29, 2008
Last updated: May 11, 2011
Last verified: May 2011
History of Changes
  Purpose

Pain remains the most debilitating symptom for adult patients suffering from complex regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current painkillers. The purpose of this study is to evaluate the efficacy and safety of ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering associated with CRPS.


Condition Intervention Phase
Complex Regional Pain Syndromes
 Drug: Placebo
Drug: Ethosuximide
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Centre. Parallel-Group, Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial on Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Maximum tolerated dose (500mg-1500mg per day) and Safety profile [ Time Frame: up to 10 weeks ] [ Designated as safety issue: No ]
    Primary outcomes will consist of the dose attained during the study and the safety (adverse event) profile. Maximum timeframe on study drug is 6 weeks. Adverse events will be collected up to one month after the trial period ends.


Secondary Outcome Measures:
  • Pain Intensity Scores on the Visual Analogue Scale (VAS) [ Time Frame: up to 7 weeks ] [ Designated as safety issue: No ]
    Pain Intensity captured on Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit)

  • Pain Intensity Scores on the Numerical Rating Scale (NRS) [ Time Frame: up to 5 weeks ] [ Designated as safety issue: No ]
    Pain Intensity using the Numerical Rating Scale will be captured by telephone every week during dose titration period (Days 3 and 6).

  • Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: up to 7 weeks ] [ Designated as safety issue: No ]
    Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit)

  • Short Form 12v2 (SF-12v2) [ Time Frame: up to 7 weeks ] [ Designated as safety issue: No ]
    Quality of Life measured on Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit)

  • Short Form McGill Pain Questionnaire (SF-MPQ) [ Time Frame: up to 7 weeks ] [ Designated as safety issue: No ]
    Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit)


Enrollment: 4
Study Start Date: September 2008
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
250mg matching placebo capsules
Experimental: 2 Drug: Ethosuximide
500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
Other Name: Zarontin

Detailed Description:

This is a single centre, parallel-group, double-blind, randomized, placebo-controlled pilot clinical trial for adults suffering from complex regional pain syndrome (CRPS).

Twelve (12) subjects diagnosed with CRPS will be enrolled and randomized to receive orally, either ethosuximide or placebo. If the maximum trial medication dosage (1500mg) is reached, the subject will be in the study for a maximum of 10 weeks from screening (Clinic Visit 1) to the end of the drug cessation period. The minimum period a subject could complete the study would be 4 weeks presuming they were not previously on any disallowed drugs and only found the 500mg dose tolerable.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age ≥18 years old;
  • Diagnosis of Complex Regional Pain Syndrome (CRPS) using International Association for the Study of Pain criteria >6 months;
  • Normal liver function (AST level <3x normal level);
  • Normal kidney function (serum creatinine <133µmol/L);
  • Full blood count, haematocrit >38%;
  • Willing and able to give informed consent and of completing study questionnaires;
  • Stable (no change in past two months) but suboptimal pain pharmacotherapy (i.e. additional pain control felt by patient and physician to be necessary);
  • Able to attend research centre according to the visit schedule;
  • Women of child-bearing potential must be using a reliable form of contraception i.e. oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or abstinence.

Exclusion Criteria:

  • Optimal response to opioids, antidepressants, anticonvulsants or anti- inflammatory medications;
  • Any history or indication of kidney or liver disease;
  • Any history of alcohol abuse;
  • Presence of diabetes;
  • Subjects taking other anti-epileptic drugs, including gabapentin, pregabalin, topiramate, phenytoin, carbamazepine, and oxcarbazepine;
  • Pregnancy (a serum bHCG pregnancy test will be performed as part of the initial blood panel);
  • Known or suspected allergy to succinimides, ethosuximide, methsuximide (Celontin®), phensuximide;
  • Any history of mental illness or disorder, which in the investigators opinion, interferes with the subjects ability to accurately report treatment response;
  • Participation in other clinical trial in the 30 days prior to enrolment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00689585

Locations
Canada, Quebec
McGill University Health Centre
Montreal, Quebec, Canada, H3G 1A4
Sponsors and Collaborators
McGill University Health Center
Louise & Alan Edwards Foundation - McGill Centre for Research on Pain
Investigators
Principal Investigator: Mark A Ware, MD McGill University Health Center
  More Information

No publications provided

Responsible Party: Mark A. Ware, Prinicipal Investigator, McGill University Health Centre - Pain Centre
ClinicalTrials.gov Identifier: NCT00689585     History of Changes
Other Study ID Numbers: GEN#07-062
Study First Received: May 29, 2008
Last Updated: May 11, 2011
Health Authority: Canada: Health Canada

Keywords provided by McGill University Health Center:
Complex Regional Pain Syndrome
Reflex Sympathetic Dystrophy
RSD
Chronic Pain
 Ethosuximide
Zarontin
Anticonvulsant

Additional relevant MeSH terms:
Somatoform Disorders
Complex Regional Pain Syndromes
Mental Disorders
Autonomic Nervous System Diseases
Nervous System Diseases
Peripheral Nervous System Diseases
 Neuromuscular Diseases
Ethosuximide
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013